Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. [PDF]
BiomedicinesFernández-Miranda JJ +3 more
europepmc +3 more sources
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Combination of clozapine with an atypical antipsychotic: a meta-analysis [PDF]
, 2017 Purpose The purpose of this paper is to review the efficacy of atypical antipsychotics in combination with clozapine. Previous meta-analyses have assessed the use of both typical and atypical antipsychotics in combination with clozapine, combination ...
McGarry, Kenneth, Rolph, Lauren
core +1 more source
Recovery from psychosis : physical health, antipsychotic medication and the daily dilemmas for mental health nurses [PDF]
, 2015 This paper considers some of the dilemmas experienced by Mental Health Nurses everyday when faced with the seemingly conflicting relationships that exist between recovery, antipsychotics and the physical health of people experiencing psychosis.
Bressington, D. +3 more
core +1 more source
Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomised controlled treatment trials [PDF]
, 2006 Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory.
Carey, P +8 more
core +1 more source
Indian Journal of Psychological Medicine, 2014 Background: Despite a large body of evidence, the issue of differences in adherence and continuation of treatment with first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in schizophrenia remains unresolved.
Nisha Warikoo +2 more
doaj +1 more source
Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
European Psychiatry, 2023 Introduction Schizophrenia affects people worldwide. In Europe, the advantages of second-generation and long-acting injectable antipsychotics (SG-LAIs) are known and used, supported by scientific evidence.
J. Galvañ, F. R. Nguepy-Keubo
doaj +1 more source
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients [PDF]
, 2008 We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic
Bilušić, Hrvoje +5 more
core +1 more source
Indian Journal of Psychological Medicine, 2014 Background: Given the paucity of research in this area, this study attempted to assess attitudes toward antipsychotic medications and its correlates among patients with schizophrenia, either on first-generation antipsychotics (FGAs) or second-generation ...
M S Karthik +4 more
doaj +1 more source
Nefazodone in psychotic unipolar and bipolar depression: A retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol [PDF]
, 2002 Although atypical antipsychotics are on the rise, traditional treatment of psychotic (or delusional) depression mostly includes the addition of classical antipsychotics to antidepressants. As there are only few data supporting this approach compared with
Born, Christoph +4 more
core +1 more source